AGT Completes Biofilm Contract With NIH.

KNOXVILLE, Tenn. -- Atmospheric Glow Technologies, Inc. (OTCBB:AGWT) (AGT) has recently completed a two year study with the National Institutes of Health demonstrating the feasibility of using its atmospheric plasma technology to destroy biofilms that impact human health. Biofilms are communities of microorganisms that are firmly attached to a surface such as a urinary catheter, a medical implant, or the inside of dental unit water lines. Once established, biofilms are extremely resistant to antibiotics and other common antimicrobial compounds. The impact on health is tremendous; a study by researchers at the Centers for Disease Control has estimated that 65% of hospital-acquired infections result from biofilm.

"We see tremendous potential for this technology," said Garth James of the Center for Biofilm Engineering at Montana State University. "We have evaluated a number of technologies aimed at combating biofilm, and are quite impressed by the performance of AGT's plasma system."

AGT is a market driven science and engineering company focused on realizing the commercial potential of the patented One Atmosphere Uniform Glow Discharge Plasma (OAUGDP(R)) technology, a method of creating plasma chemistry in air at atmospheric pressure. Management believes that the OAUGDP(R) is an exciting breakthrough in proprietary technology offering capabilities that other plasma technologies do not provide. Moreover, AGT is working to expand the applicability of its OAUGDP(R) technology and has targeted new market and product opportunities with the goal of creating additional shareholder value. AGT's technology has been the recipient of numerous federal contracts and grants and recognition awards. Additional information is available at http://www.atmosphericglow.com.

Statements in this release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In addition, words such as "believes", "anticipates", "expects", and similar expressions are intended to identify forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of events of the company, or events, or timing of events, relating to the company to differ materially from any future results, performance, or achievements of the forward-looking statements. The company cannot assure that it will be able to anticipate or respond timely to the changes, which could adversely affect its operating results in one or more fiscal quarters. Results of operations in any past period should not be considered indicative of results to be expected in future periods. Fluctuations in operating results may result in fluctuations in the price of the company's securities.